SCHEMBL25428892

SCHEMBL25428892

FC(F)(F)c1ccc(Oc2nccnc2-c2ccc3[nH]nnc3c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 3/20 0.37
▸ CCNB2 O95067 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ GSK3A P49840 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ CCNB3 Q8WWL7 1/20 0.37
▸ PDE10A Q9Y233 6/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ MAP2K4 P45985 2/20 0.36
▸ MAPKAPK3 Q16644 2/20 0.36
▸ MAPK6 Q16659 2/20 0.36
▸ MAPKAPK2 P49137 1/20 0.36
▸ CHEK2 O96017 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30544130 1.00 TRPV1 (0.37) TRPV1CCNB2CDK1CCNB1GSK3A
SCHEMBL25427930 0.84 PDE10A (0.45) TRPV1PDE10A
SCHEMBL30544141 0.84 PDE10A (0.45) TRPV1PDE10A
SCHEMBL30544158 0.84 CCNB2 (0.37) TRPV1CCNB2CDK1CCNB1GSK3A
SCHEMBL25340897 0.84 CCNB2 (0.37) TRPV1CCNB2CDK1CCNB1GSK3A
SCHEMBL25428722 0.82 TRPV1 (0.35) TRPV1CCNB2CDK1CCNB1GSK3A
SCHEMBL30544083 0.82 TRPV1 (0.35) TRPV1CCNB2CDK1CCNB1GSK3A
SCHEMBL25428430 0.78 TRPV1 (0.36) TRPV1CCNB2CDK1CCNB1GSK3A
SCHEMBL25430912 0.78 TRPV1 (0.47) TRPV1
SCHEMBL30544022 0.78 TRPV1 (0.36) TRPV1CCNB2CDK1CCNB1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023146511-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146511-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
Send feedback